Form 4: SANUWAVE Director Blizard to Acquire Stock Options
Insider Transaction Report
SANUWAVE Health, Inc. Director Jeffrey Blizard reported the future acquisition of 1,342 stock options, fully vested at grant on September 30, 2025, with an exercise price of $37.48.
Summary
- Director Jeffrey Blizard is set to acquire 1,342 stock options in SANUWAVE Health, Inc. (SNVW) on September 30, 2025.
- The stock options have an exercise price of $37.48 per share.
- The options will be fully vested at the grant date, September 30, 2025.
- The expiration date for these stock options is September 30, 2030.
- Following this transaction, Blizard will beneficially own 1,342 derivative securities directly.
Sentiment
Score: 6
Explanation: The acquisition of stock options by a director is generally viewed as a positive signal, indicating confidence and aligning interests with shareholders, though the future transaction date is unusual for a Form 4.
Positives
- The acquisition of stock options by a director generally indicates alignment of management's interests with shareholder value creation.
- The options are fully vested at the grant date, providing immediate equity exposure.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Jeffrey Blizard, a director of SANUWAVE Health, Inc., was granted 1,342 stock options as part of his compensation package.
Stakeholder Impact
- Shareholders: The grant of stock options to a director aligns management's interests with shareholder value creation, potentially incentivizing performance.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of earliest transaction, grant date for stock options, and date options become fully vested. |
| 10/02/2025 | Date the Form 4 was signed by the attorney-in-fact. |
| 09/30/2030 | Expiration date of the stock options. |
Recommendation
holdThe Form 4 reports a routine insider transaction involving the acquisition of stock options by a director. While this generally signals confidence and aligns interests, the relatively small number of options (1,342) and the nature of the transaction (compensation) do not provide sufficient new information to warrant a strong buy or sell recommendation. It is a minor positive signal for long-term alignment.
Keywords
SANUWAVE Health, SNVW, Jeffrey Blizard, Stock Options, Insider Trading, Director Compensation, SEC Form 4, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.